David Yeomans, PhD, associate professor of anesthesiology, perioperative, and pain medicine at Stanford University School of Medicine, discusses the challenges of evaluating pain associated with migraine.
Secondary symptoms like nausea also need to be taken into account when evaluting migraine treatment efficacy, said David Yeomans, PhD, associate professor of anesthesiology, perioperative, and pain medicine at Stanford University School of Medicine.
Transcript
Because pain is subjective, can you elaborate on some of the challenges of studying migraine?
It's a fairly standard way that companies, for example, will do that, that the FDA has accepted that methodology. But you're right, the pain is clearly subjective. But what you do is you look at pain, you've probably heard of the 0 to 10 scale. You go to the doctor, they say how much pain, "Oh it's a 6." With migraine, they use a different scale. It's a 4-point scale, where you say, severe, moderate, mild or none. And it's a little easier for people to categorize. And so there's that. What you're looking for is a decrease from severe or moderate down to mild or none. That's considered a positive response.
But you also have to look at the secondary symptoms. So, what's called the most bothersome secondary symptoms, like nausea, or photophobia, or phonophobia. So whatever is the most bothersome to a patient. You look at not only the pain level, but how much your treatment is affecting this secondary thing.
There's also some biomarkers that people are investigating. For example, we know when these trigeminal neurons are active, they release something called CGRP, calcitonin gene-related peptide. It's a neurotransmitter. That's the target for some of these newer drugs that have come out, either CGRP antibodies or CGRP antagonists to block CGRP. Turns out, you can measure CGRP either in the blood or the saliva. It looks like when CGRP is elevated, that's a clear strong correlation to how much pain you have. It's not established yet, that is to say, the FDA doesn't accept it yet. But it looks like that should be a decent biochemical marker of how active these pain neurons in the trigeminal neuron are. Pain is not in the peripheral nerves, pain is up here in the cortex in the brain. There's a lot of steps in between. But for something like this, just measuring CGRP seems like it's a pretty good indicator of how much pain a person's having.
Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk
November 21st 2024Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.
Read More
Study Highlights Key RA-ILD Risk Factors, Urges Early Screening
November 20th 2024This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed
November 20th 2024Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.
Read More
OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM
November 19th 2024The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).
Read More